Comparative cardiovascular morbidity and mortality in patients taking different insulin regimens for type 2 diabetes: a systematic review

BMJ Open
Hilary I PriceJohn-Michael Gamble

Abstract

To summarise the literature evaluating the association between different insulin regimens and the incidence of cardiovascular morbidity and mortality in adults with type 2 diabetes. Systematic review. Multiple biomedical databases (The Cochrane Library, PubMed, EMBASE, and International Pharmaceutical Abstracts) were searched from their inception to February 2014. References of included studies were hand searched. Randomised controlled trials (RCTs), cohort studies or case-control studies examining adults (≥18 years) with type 2 diabetes taking any type, dose and/or regimen of insulin were eligible for inclusion in this review. Primary outcomes were cardiovascular morbidity and mortality including fatal and/or non-fatal myocardial infarction, fatal and/or non-fatal stroke, major adverse cardiac events and cardiovascular death. All-cause mortality was assessed as a secondary outcome. Of the 3122 studies identified, 2 RCTs and 6 cohort studies were selected. No case-control studies met the inclusion criteria. The studies examined a total of 109,910 patients. Quantitative synthesis of the results from included studies was not possible due to a large amount of clinical heterogeneity. Each study evaluated cardiovascular outcomes acr...Continue Reading

References

Sep 27, 2000·Journal of Clinical Epidemiology·D MoherA Liberati
Aug 13, 2004·International Journal of Obesity and Related Metabolic Disorders : Journal of the International Association for the Study of Obesity·R G Bretzel
Jan 22, 2005·Diabetic Medicine : a Journal of the British Diabetic Association·M J MuisR P Stolk
Apr 18, 2008·Diabetes Research and Clinical Practice·Nicole M Engel-NitzVivian Fonseca
Jun 10, 2008·The New England Journal of Medicine·Anushka PatelFlorence Travert
Jun 10, 2008·The New England Journal of Medicine·UNKNOWN Action to Control Cardiovascular Risk in Diabetes Study GroupWilliam T Friedewald
Jul 10, 2008·Pharmacoepidemiology and Drug Safety·David J MargolisBrian L Strom
Dec 19, 2008·The New England Journal of Medicine·William DuckworthUNKNOWN VADT Investigators
Jul 22, 2009·Pharmacoepidemiology and Drug Safety·Kristian B FilionJames M Brophy
Oct 1, 2009·Diabetes, Obesity & Metabolism·J-M GambleJ A Johnson
Oct 24, 2009·Diabetologia·B Draznin
Feb 3, 2011·Current Atherosclerosis Reports·Shailesh NandishRobert Chilton
Jul 9, 2011·Diabetes, Obesity & Metabolism·C J Currie, J A Johnson
May 9, 2012·International Journal of Technology Assessment in Health Care·Andra MorrisonDanielle Rabb
May 15, 2012·International Journal of Clinical Pharmacology and Therapeutics·Stephan KressWolfgang Rathmann
Jun 13, 2012·The New England Journal of Medicine·Hertzel C GersteinSalim Yusuf
Jun 23, 2012·The Journal of Clinical Endocrinology and Metabolism·Ajay ChaudhuriVivian Fonseca
Feb 2, 2013·The Journal of Clinical Endocrinology and Metabolism·Craig J CurrieChristopher Ll Morgan
Sep 28, 2013·Canadian Journal of Diabetes·Lawrence A LeiterAnatoly Langer
Nov 20, 2013·Thérapie·Rémy BoussageonCatherine Cornu
Dec 21, 2013·Diabetes Care·UNKNOWN American Diabetes Association

❮ Previous
Next ❯

Citations

Dec 10, 2015·Endocrine·Apostolos TsapasEleni Bekiari
Oct 25, 2016·Journal of Cardiothoracic and Vascular Anesthesia·Giovanni LandoniRinaldo Bellomo
Aug 21, 2020·BMC Medicine·Hubert KolbStephan Martin
Sep 4, 2020·Current Drug Safety·Anna Pietraszek

❮ Previous
Next ❯

Methods Mentioned

BETA
pharmacotherapy
MDA

Software Mentioned

Stata
Cochrane

Related Concepts

Related Feeds

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.